An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists

BACKGROUND: Interferon (IFN) beta drugs have been approved for the treatment of relapsing forms of multiple sclerosis (RMS) for more than 20 years and are considered to offer a favourable benefit-risk profile. In July 2014, subcutaneous (SC) peginterferon beta-1a 125 μg dosed every 2 weeks, a pegyla...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolb-Mäurer, Annette, Sunderkötter, Cord, Kukowski, Borries, Meuth, Sven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570848/
https://www.ncbi.nlm.nih.gov/pubmed/31202258
http://dx.doi.org/10.1186/s12883-019-1354-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570848/
https://www.ncbi.nlm.nih.gov/pubmed/31202258
http://dx.doi.org/10.1186/s12883-019-1354-y

Ejemplares similares